

- Renal biopsy (*Cont.*):
 assessment of, 1836–1837
 atlas of, 62e-1–10
 in chronic kidney disease, 1820
 in diabetic nephropathy, 62e-8f, 1844
 in Fabry's disease, 62e-7f, 1846
 in focal segmental glomerulosclerosis, 62e-1f, 62e-2f
 in glomerular diseases, 62e-1–6f, 1836–1837
 in granulomatosis with polyangiitis, 62e-5f, 386e-1, 386e-6f, 1840
 in hemolytic-uremic syndrome, 62e-9f, 1848
 in hypertensive nephrosclerosis, 62e-9f, 1848
 in IgA nephropathy, 62e-3f, 1839
 in lupus nephritis, 62e-5f, 1838
 in membranoproliferative glomerulonephritis, 62e-3f, 62e-4f, 1841
 in membranous glomerulonephritis, 62e-3f, 1843
 in minimal change disease, 62e-1f, 1841–1842
 in multiple myeloma, 62e-7f, 1859f
 in oxalosis, 62e-10f
 in poststreptococcal glomerulonephritis, 62e-2f, 1837
 in pyelonephritis, 62e-10f
 stains for, 1836
 in vasculitic syndromes, 386e-1
- Renal cell carcinoma (RCC), 578
 clinical features of, 578
 epidemiology of, 578
 epigenetic silencing in, 102e-7
 genetic considerations in, 578, 578t
 intrahepatic cholestasis in, 284
 metastatic, 604t
 paraneoplastic syndromes in, 578, 612, 612t
 pathology of, 578, 578t
 prognosis of, 578, 579, 579f
 staging of, 578, 579f
 treatment of, 102e-5t, 102e-17, 103e-19, 103e-22, 578–579
 tuberous sclerosis and, 578, 1854
 von Hippel-Lindau syndrome and, 578, 1854, 2343
- Renal colic, 1866, 1868, 1872. *See also* Nephrolithiasis
- Renal coloboma syndrome, 1855
- Renal cysts. *See* Polycystic kidney disease
- Renal disease/failure
 acute. *See* Acute kidney injury (AKI)
 chronic. *See* Chronic kidney disease (CKD)
 glomerular. *See* Glomerular diseases
 nephrolithiasis. *See* Nephrolithiasis
 tubulointerstitial diseases. *See* Tubulointerstitial diseases
 vascular. *See* Renovascular disease
- Renal natriuretic peptide, 332e-9
- Renal osteodystrophy, 291, 2478
- Renal pelvis, carcinoma of. *See* Kidney cancer; Renal cell carcinoma (RCC)
- Renal stem cells, 453t
- Renal transplantation. *See* Kidney transplantation
- Renal tubular acidosis (RTA)
 distal (type I)
 genetic considerations in, 332e-7t
 hypokalemia in, 307
 metabolic acidosis in, 320
 in Sjögren's syndrome, 64e-6
 urinary tract obstruction and, 1872
 proximal (type II)
 genetic considerations in, 332e-7t
 metabolic acidosis in, 320
 type IV, 320, 2425
- Renal tubular defects, 289t
- Renal vein, renin ratio, 1618
- Renal vein thrombosis, 1866
- Renin
 ectopic production of, 609t
 pNET secreting, 559t, 571
 renal vein renin ratio, 1618
 in shock, 1745
 synthesis and secretion of, 1614
- Renin-angiotensin-aldosterone (RAA) system
 assessment of, 2311
 in blood pressure regulation, 1613–1614, 1614f
 in edema, 250, 252
 in glomerular filtration rate regulation, 332e-2–3, 332e-2f
 in heart failure pathogenesis, 1502, 1502f
 in mineralocorticoid synthesis, 2311, 2311f
 in potassium regulation, 304–305, 310
 in sodium regulation, 332e-10–11
- Renovascular disease, 1627
 atheroembolic, 1629, 1806t
 diagnosis of, 1628, 1628f, 1628t
 hypertension, 1614, 1617–1618, 1622, 1630
 hypertensive nephrosclerosis, 62e-9f, 1617, 1630, 1835t, 1847–1848
 renal artery stenosis. *See* Renal artery stenosis
 thromboembolic, 1629–1630, 1630f, 1866
 thrombotic microangiopathic. *See* Thrombotic microangiopathy, renal
- Reoviruses
 gene expression and replication in, 214e-4
 reservoirs and vectors of, 1305
 structure of, 214e-2t, 214e-3f, 1295
- Reovirus infections, 1311–1312t, 1319
- Repaglinide, 2413, 2414t
- Repetition, assessment of, 177
- Representativeness heuristic, 19
- Reproduction number (R0), 778
- Reproductive system disorders. *See* Female reproductive system disorders; Male reproductive system disorders
- Reptilase time, 407
- Reptile bites. *See* Snakebites
- Research
 ethical issues in, 17e-4
 physician engaged in, 7
 skews in, global effects of, 13e-4
- Reserpine, 1624t
- Resident physicians, working hours of, 7
- Resident stem cells, 453
- Residual volume (RV), 306e-1f, 306e-2, 306e-2f, 306e-5f
- Resilience, 86e-1t, 86e-3, 86e-7
- Resistance strength training, 165
- Resistance to thyroid hormone (RTH), 435, 2286t, 2287
- Respiration
 in hypothermia, 478e-2t
 respiratory rate, 47e-3
 in shock, 1730t, 1746
- Respiratory acidosis, 322
 acid-base nomogram, 316f
 clinical features of, 322
 compensatory responses in, 316t, 322
 drug-induced, 322
 etiology of, 322–323, 323t
 hyperkalemia in, 309
 in mixed acid-base disorders, 316t, 317
 treatment of, 323
- Respiratory alkalosis, 323
 acid-base nomogram, 316f
 compensatory responses in, 316t
 diagnosis of, 324
 etiology of, 323–324, 323t
 in hypoxia, 248
 in mixed acid-base disorders, 316t, 317
 in sepsis/septic shock, 1756
 treatment of, 324
- Respiratory bronchiolitis-associated ILD, 1713
- Respiratory disorders. *See also* Lung disease; Respiratory tract infections
 approach to the patient, 1661
 categories of, 1661, 1661t
 chest pain in, 1661
 clinical features of, 1661–1662
 clubbing in, 1662
 cough in, 1661
 deaths from, by sex, 6e-1t
 diagnosis of, 1663
 bronchoscopy, 1663, 1667, 1668
 chest radiography, 1663, 1664f
 CT, 1663, 1664–1666, 1664f, 1665f
- emerging techniques, 1668
 endobronchial ultrasound, 1668
 flexible fiberoptic bronchoscopy, 1667
 gas exchange measurement, 306e-6
 mediastinoscopy, 1668
 mediastinotomy, 1668
 MRI/MRA, 1666, 1667f
 nuclear medicine techniques, 1664
 percutaneous needle aspiration, 1667
 PET, 1667
 pulmonary angiography, 1667–1668
 pulmonary function testing, 1662–1663
 sputum analysis. *See* Sputum analysis
 thoracentesis, 1667
 thoracoscopy, 1668
 thoracotomy, 1669
 transbronchial needle aspiration, 1669
 ultrasound, 1663–1664
 ventilatory function measurement, 306e-6
 video-assisted thoracic surgery, 1668–1669
 virtual bronchoscopy, 1666, 1666f
- dyspnea in, 47e-1t, 47e-2, 1661
 hemoptysis in, 1661
 history in, 1661–1662
 inhaled agents associated with, 1662
 obesity and, 415e-6
 obstructive patterns, 306e-5–6
 pathophysiology of, 306e-1
 physical examination in, 1662
 pulmonary function values in, 306e-5–6, 306e-5f
 restrictive patterns, 306e-5–6, 306e-5f
 risk factors for, 1662
 smoking and, 1662, 2729, 2730t
 in women, 6e-2f
- Respiratory failure
 in ARDS. *See* Acute respiratory distress syndrome (ARDS)
 in critically ill patient, 1731–1732
 hypercarbic, 1740
 in hyponatremia, 300
 hypoxemic, 1740
 hypoxia in, 247
 pathophysiology of, 1731–1732
 perioperative, 1732
 in shock, 1731
- Respiratory function
 disturbances of. *See* Respiratory disorders
 flow-related properties of, 306e-2, 306e-2f, 306e-3f, 1733, 1734f
 gas exchange, 306e-3–4
 during sleep, 187
 ventilation-perfusion heterogeneity, 306e-4, 306e-4f
 ventilatory adequacy, 306e-3
 volume-related properties of, 306e-1–2, 306e-1f, 1733
 work of breathing, 306e-2–3
 “Respiratory hygiene and cough etiquette,” 917
- Respiratory muscles
 assessment of strength of, 306e-6
 fatigue/weakness of, 306e-5, 1731–1732
 hypoperfusion of, 1732
- Respiratory quotient, 306e-3
- Respiratory sinus arrhythmia, 278e-1f
- Respiratory syncytial virus infections. *See* Human respiratory syncytial virus (HRSV) infections
- Respiratory tract infections
 adenovirus. *See* Adenovirus infections
Aspergillus. *See* *Aspergillus* infections, respiratory tract
 asthma exacerbations and, 1671
C. pneumoniae, 1173–1174
 chronic *P. aeruginosa*, 1045–1046
 COPD exacerbations and. *See* Chronic obstructive pulmonary disease (COPD), exacerbations of
 coronavirus. *See* Coronavirus infections
 in cystic fibrosis, 1697
 enterovirus, 965t
 epiglottitis. *See* Epiglottitis
 hemoptysis in, 245
 HMPV, 965t, 1206